Lv7
3580 积分 2022-07-13 加入
Review of dose justifications for antibody-drug conjugate approvals from clinical pharmacology perspective: A focus on exposure-response analyses
11天前
已完结
Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: Case studies of vepdegestrant (ARV-471) and bavdegalutamide (ARV-110)
1个月前
已完结
Misconceptions among medicinal chemists regarding ADME and PK optimization
1个月前
已完结
Application of humanized FcRn mouse model for in vivo testing of therapeutic antibodies (131.37)
2个月前
已关闭
Translational Approaches for Human Pharmacokinetics and Pharmacodynamics Prediction of Antibody-drug Conjugates: Bridging Complexity from Bench to Bedside
2个月前
已完结
The expanding role of formulations to enable oral delivery of poorly water-soluble drugs
2个月前
已完结
Predicting the Pharmacokinetics of T‐Cell Engagers as a Function of Target‐Mediated Drug Disposition
2个月前
已关闭
Risk Factors for CRS and ICANS with Tarlatamab in Small Cell Lung Cancer and Associated Efficacy Outcomes: Insights from Clinical Practice
2个月前
已关闭
Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report
2个月前
已关闭
The CD58–CD2 axis in cancer immune evasion
3个月前
已完结
皖公网安备34019202002308
